دوره 1، شماره 3 - ( 6-1394 )                   جلد 1 شماره 3 صفحات 1-10 | برگشت به فهرست نسخه ها



DOI: 10.18869/acadpub.pbr.1.3.1

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Reddy H, Gopinath C, Saleem Thattakudian Sheikuduman M. Dabigatran etexilate - A novel oral anticoagulant for bleeding complications. mazums-pbr. 2015; 1 (3) :1-10
URL: http://pbr.mazums.ac.ir/article-1-68-fa.html
Dabigatran etexilate - A novel oral anticoagulant for bleeding complications. . 1394; 1 (3) :1-10

URL: http://pbr.mazums.ac.ir/article-1-68-fa.html


چکیده:   (1364 مشاهده)

Thromboembolic disease is a common cause of morbidity and mortality. Thrombin plays a key role in thrombotic events and thrombin inhibition represents a therapeutic event for thromboembolic events and has been identified as a target of therapy of its pivotal role in coagulation process. Anticoagulation is a major intervention for the management of arterial and venous thromboembolic events. Dabigatran etexilate is an orally effective anti-thrombin drug, several animal and human trials were conformed the efficacy of this drug in reduction of major bleeding in related to acute coronary syndrome, knee replacement surgery and venous thromboembolism conditions. The therapeutic use of this drug also shows limited side effects to select the dabigatran as promising therapeutic agent in bleeding complications.

متن کامل [PDF 481 kb]   (656 دریافت)    
نوع مطالعه: مروری | موضوع مقاله: فارماکولوژی

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
کد امنیتی را در کادر بنویسید

کلیه حقوق این وب سایت متعلق به می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2015 All Rights Reserved | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb